The Patent Finder

Terms ending in 2038

Araxes Pharma LLC

Every in-force patent on Araxes Pharma LLC's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,274,093Fused Bicyclic Benzoheteroaromatic Compounds and Methods of Use Thereof
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 11,279,6891-(3-(6-(3-Hydroxynaphthalen-1-YL)BENZOFURAN-2-YL)AZETIDIN-1 YL)PROP-2-EN-1-ONE Derivatives and Similar Compounds as Kras G12C Modulators for Treating Cancer
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,736,897Compounds and Methods of Use Thereof for Treatment of Cancer
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 10,745,385Covalent Inhibitors of Kras
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
US 11,639,346Quinazoline Derivatives as Modulators of Mutant Kras, Hras or Nras
In force
 · High confidence
Araxes Pharma LLCIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited